Myriam Calle Rubio1, Juan Luis Rodríguez Hermosa2, Juan José Soler-Cataluña3, José Luis López-Campos4, Bernardino Alcazar Navarrete5, Joan B Soriano6, José Miguel Rodríguez Gónzalez-Moro7, Manuel E Fuentes Ferrer8, Marc Miravitlles9. 1. Servicio de Neumología, Instituto de Investigación Sanitaria (IdISSC), Hospital Clínico San Carlos, Madrid, España; Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, España. Electronic address: mcallerubio@gmail.com. 2. Servicio de Neumología, Instituto de Investigación Sanitaria (IdISSC), Hospital Clínico San Carlos, Madrid, España; Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, España. 3. Servicio de Neumología, Hospital de Arnau de Villanova, Valencia, España; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, España. 4. CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, España; Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, España. 5. Servicio de Neumología, Hospital de Alta Resolución de Loja, Granada, España. 6. Instituto de Investigación, Hospital Universitario de la Princesa (IISP), Universidad Autónoma de Madrid, Madrid, España. 7. Servicio de Neumología, Hospital Universitario Príncipe de Asturias, Alcalá de Henares (Madrid), España. 8. Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, España; UGC de Medicina Preventiva, Instituto de Investigación Sanitaria (IdISSC), Hospital Clínico San Carlos, Madrid, España. 9. Servicio de Neumología, Hospital Universitario Vall d'Hebrón, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, España.
Abstract
INTRODUCTION: EPOCONSUL is the first national audit to analyze medical care for COPD in pulmonology departments in Spain. The main objective was to perform a retrospective analysis to determine the distribution of GesEPOC 2017 COPD risk levels and to evaluate clinical activity according to the new recommendations. MATERIAL AND METHODS: This is a cross-sectional clinical audit in which consecutive COPD cases were recruited over one year. The study evaluated risk and clinical phenotype according to GesEPOC 2017, and their correlation with the clinical interventions employed. RESULTS: The most common risk category was high risk (79.8% versus 20.2%; p < 0.001), characterized by a higher level of severity on BODE and BODEx indexes, and a higher comorbidity burden. The most common phenotype was non-exacerbator. The most commonly used treatment in low-risk patients was bronchodilator monotherapy (34.8%) and triple therapy in high-risk patients (53.7%). High risk was most frequently characterized by phenotype (57.6% versus 52%; p = 0.014) and pulmonary function test results: lung volume (47.7% versus 35.8%; p < 0.001), lung diffusion (51.4% versus 42.1%; p < 0.001) and walk test (37.8% versus 15.8%; p < 0.001). CONCLUSIONS: Most patients treated in pulmonology departments were high-risk and non-exacerbator phenotype. Clinical interventions differed according to risk level and mainly followed GesEPOC recommendations, although there is significant room for improvement.
INTRODUCTION: EPOCONSUL is the first national audit to analyze medical care for COPD in pulmonology departments in Spain. The main objective was to perform a retrospective analysis to determine the distribution of GesEPOC 2017 COPD risk levels and to evaluate clinical activity according to the new recommendations. MATERIAL AND METHODS: This is a cross-sectional clinical audit in which consecutive COPD cases were recruited over one year. The study evaluated risk and clinical phenotype according to GesEPOC 2017, and their correlation with the clinical interventions employed. RESULTS: The most common risk category was high risk (79.8% versus 20.2%; p < 0.001), characterized by a higher level of severity on BODE and BODEx indexes, and a higher comorbidity burden. The most common phenotype was non-exacerbator. The most commonly used treatment in low-risk patients was bronchodilator monotherapy (34.8%) and triple therapy in high-risk patients (53.7%). High risk was most frequently characterized by phenotype (57.6% versus 52%; p = 0.014) and pulmonary function test results: lung volume (47.7% versus 35.8%; p < 0.001), lung diffusion (51.4% versus 42.1%; p < 0.001) and walk test (37.8% versus 15.8%; p < 0.001). CONCLUSIONS: Most patients treated in pulmonology departments were high-risk and non-exacerbator phenotype. Clinical interventions differed according to risk level and mainly followed GesEPOC recommendations, although there is significant room for improvement.
Authors: Javier de Miguel-Díez; Rodrigo Jiménez-García; Ana López de Andrés; Fernando Zaragoza Arnáez Journal: Clin Drug Investig Date: 2019-07 Impact factor: 2.859
Authors: Myriam Calle Rubio; Juan José Soler-Cataluña; José Luis López-Campos; Bernardino Alcázar Navarrete; José Miguel Rodríguez González-Moro; Joan B Soriano; Manuel E Fuentes Ferrer; Juan Luis Rodriguez Hermosa Journal: PLoS One Date: 2019-02-06 Impact factor: 3.240
Authors: Jose Luis Lopez-Campos; Laura Carrasco-Hernandez; Esther Quintana-Gallego; Carmen Calero-Acuña; Eduardo Márquez-Martín; Francisco Ortega-Ruiz; Joan B Soriano Journal: Ther Adv Respir Dis Date: 2019 Jan-Dec Impact factor: 4.031
Authors: Juan Luis Rodríguez Hermosa; Antonia Fuster Gomila; Luis Puente Maestu; Carlos Antonio Amado Diago; Francisco Javier Callejas González; Rosa Malo De Molina Ruiz; Manuel E Fuentes Ferrer; Jose Luis Alvarez-Sala; Myriam Calle Rubio Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-01-08
Authors: Helgo Magnussen; Sarah Lucas; Therese Lapperre; Jennifer K Quint; Ronald J Dandurand; Nicolas Roche; Alberto Papi; David Price; Marc Miravitlles Journal: Respir Res Date: 2021-01-21
Authors: Laura Carrasco Hernández; Candela Caballero Eraso; Borja Ruiz-Duque; María Abad Arranz; Eduardo Márquez Martín; Carmen Calero Acuña; Jose Luis Lopez-Campos Journal: J Clin Med Date: 2021-04-15 Impact factor: 4.241
Authors: Juan Luis Rodriguez Hermosa; Antonia Fuster Gomila; Luis Puente Maestu; Carlos Antonio Amado Diago; Francisco Javier Callejas González; Rosa Malo De Molina Ruiz; Manuel E Fuentes Ferrer; Jose Luis Álvarez Sala-Walther; Myriam Calle Rubio Journal: JMIR Mhealth Uhealth Date: 2020-03-19 Impact factor: 4.773
Authors: María Merino; Renata Villoro; Álvaro Hidalgo-Vega; Concepción Carmona Journal: Health Qual Life Outcomes Date: 2019-12-30 Impact factor: 3.186